Allogene Therapeutics (ALLO) Wānana Kūʻai Kūʻai
Allogene Therapeutics
Kaʻu kumukūʻai hope$1.65Hoʻohou ʻia 25 Kep. 2026 19:59 UTC
Hoʻololi-1.20%
Hōʻoia AI: ALLO
Hoʻopuka ka AI i kahi kumukūʻai pahuhopu no ka lā kālepa aʻe, ka hopena pule a me ka hopena mahina. Hoʻomākaukau ʻia ka hoʻololi mai ka kumukūʻai hou loa. He helnau kūlana helu wale nō kēia, ʻaʻole he ʻōlelo aʻoaʻo hoʻopukapuka.
Kumukūʻai ma luna o nā mahina 6 i hala
Hōʻike ʻo Premium i nā pahuhopu kumukūʻai o ka AI no 1 lā, 1 pule a me 1 mahina no kēia a me nā stock ʻē aʻe.
Wehe iā Premium🔒 Moʻolelo hōʻike wānana
The forecast track record — every past forecast next to the actual close — is part of Premium.
Wehe iā PremiumE pili ana i kēia Hui
Allogene Therapeutics, Inc. is a biotechnology company that develops T-cell therapies using allogeneic chimeric antigen receptors for the treatment of blood cancers and solid tumors. Allogene Therapeutics serves patients in California.
